GeneXpert Performance Evaluation for Linkage to Tuberculosis Care

NACompletedINTERVENTIONAL
Enrollment

10,644

Participants

Timeline

Start Date

October 22, 2018

Primary Completion Date

March 31, 2020

Study Completion Date

July 31, 2022

Conditions
Tuberculosis, PulmonaryRifampicin Resistant Tuberculosis
Interventions
DEVICE

GeneXpert I

Onsite molecular testing with GeneXpert I as a replacement for microscopy

BEHAVIORAL

Process re-design

Research and Uganda NTLP staff will engage health center staff in a discussion of how to re-organize clinical, laboratory and pharmacy services to enable same-day TB diagnosis and treatment.

OTHER

Performance Feedback

Feedback of TB diagnostic evaluation quality indicators to health center staff

Trial Locations (20)

Unknown

St Francis Njeru Health Center III, Buikwe

Busana Health Center III, Busana

Busesa Health Center IV, Busesa

Buwama Health Center III, Buwama

Iganga TC, Iganga

Bukulula Health Center IV, Kalungu

Nazigo Health Center III, Kayunga

Kiganda Health Center IV, Kiganda

Kira Health Center III, Kira

Lugasa Health Center III, Lugala

Bishop Asili Health Center, Luwero

Kinoni Health Center III, Lwengo

Kityerera Health Center IV, Mayuge

Malongo Health Center III, Mayuge

Mayuge Health Center III, Mayuge

Wabulungu Health Center III, Mayuge

Malangala Health Center III, Mityana

Lwampanga Health Center III, Nakasongola

Namungalwe Health Center III, Namungalwe

Nankandulo Health Center IV, Nankandulo

All Listed Sponsors
collaborator

Makerere University

OTHER

collaborator

Johns Hopkins Bloomberg School of Public Health

OTHER

collaborator

London School of Hygiene and Tropical Medicine

OTHER

collaborator

Yale University

OTHER

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of California, San Francisco

OTHER

NCT03044158 - GeneXpert Performance Evaluation for Linkage to Tuberculosis Care | Biotech Hunter | Biotech Hunter